Composite Type 2 Biomarker Strategy vs a Symptom Risk–Based Algorithm to Adjust Corticosteroid Dose in Patients With Severe Asthma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Composite Type-2 Biomarker Strategy Versus a Symptom-Risk-Based Algorithm to Adjust Corticosteroid Dose in Patients With Severe Asthma: A Multicentre, Single-Blind, Parallel Group, Randomised Controlled Trial
Lancet Respir Med 2020 Sep 07;[EPub Ahead of Print], LG Heaney, J Busby, CE Hanratty, R Djukanovic, A Woodcock, SM Walker, TC Hardman, JR Arron, DF Choy, P Bradding, CE Brightling, R Chaudhuri, DC Cowan, AH Mansur, SJ Fowler, RM Niven, PH Howarth, JL Lordan, A Menzies-Gow, TW Harrison, DS Robinson, CTJ Holweg, JG Matthews, ID PavordFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.